Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Oct;29(10):896-905.
doi: 10.1002/da.21977. Epub 2012 Jul 5.

Patient treatment preference as a predictor of response and attrition in treatment for chronic depression

Dana Steidtmann  1 , Rachel Manber, Bruce A Arnow, Daniel N Klein, John C Markowitz, Barbara O Rothbaum, Michael E Thase, James H Kocsis
Affiliations
Randomized Controlled Trial

Patient treatment preference as a predictor of response and attrition in treatment for chronic depression

Dana Steidtmann et al. Depress Anxiety. 2012 Oct.

Abstract

Background: Findings regarding the relationship between patient treatment preference and treatment outcome are mixed. This is a secondary data analysis investigating the relationship between treatment preference, and symptom outcome and attrition in a large two-phase depression treatment trial.

Methods: Patients met DSM-IV criteria for chronic forms of depression. Phase I was a 12-week, nonrandomized, open-label trial in which all participants (n = 785) received antidepressant medication(s) (ADM). Phase I nonremitters were randomized to Phase II, in which they received 12 weeks of either cognitive-behavioral system of psychotherapy (CBASP) + ADM (n = 193), brief supportive psychotherapy (BSP) + ADM (n = 187), or ADM only (n = 93). Participants indicated their treatment preference (medication only, combined treatment or no preference) at study entry. Symptoms were measured at 2-week intervals with the 24-item Hamilton Rating Scale for Depression (HAM-D).

Results: A large majority of patients reported a preference for combined treatment. Patients who preferred medication only were more likely to endorse a chemical imbalance explanation for depression, whereas those desiring combined treatment were more likely to attribute their depression to stressful experiences. In Phase I, patients who expressed no treatment preference showed greater rates of HAM-D symptom reduction than those with any preference, and patients with a preference for medication showed higher attrition than those preferring combined treatment. In Phase II, baseline treatment preference was not associated with symptom reduction or attrition.

Conclusions: Treatment preferences may moderate treatment response and attrition in unexpected ways. Research identifying factors associated with differing preferences may enable improved treatment retention and response.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Participant flowchart.
Figure 2
Figure 2
Mean HAM-D scores across Phase I for patients with and without a treatment preference.
See this image and copyright information in PMC

References

    1. World Health Organiziation . Depression Management Fact Sheet. 2011.
    1. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602. - PubMed
    1. Swift JK, Callahan JL, Vollmer BM. Preferences. J Clin Psychol. 2011;67(2):155–65. - PubMed
    1. Kwan BM, Dimidjian S, Rizvi SL. Treatment preference, engagement, and clinical improvement in pharmacotherapy versus psychotherapy for depression. Behav Res Ther. 2010;48(8):799–804. - PMC - PubMed
    1. van Schaik DJ, Klijn AF, van Hout HP, et al. Patients' preferences in the treatment of depressive disorder in primary care. General hospital psychiatry. 2004;26(3):184–9. - PubMed

Publication types

MeSH terms

Substances